NanoMedSyn is a deep‑tech biotech company enabling precise, receptor‑guided delivery to lysosomes to potentiate the efficacy of diverse therapeutic modalities. Our platform is designed to improve intracellular uptake and routing, addressing a major bottleneck for biologics and advanced modalities across high‑value disease areas.
At the core of NanoMedSyn is a patented library of AMFA glycovectors engineered to selectively engage the mannose 6‑phosphate receptor (M6PR)—the primary cellular gateway to lysosomes. Conjugated to antibodies, enzymes, or nanoparticle systems, AMFA moieties enhance tissue targeting, cellular internalization, and lysosomal delivery, unlocking potency where conventional delivery falls short.
The platform has achieved preclinical validation and demonstrates broad applicability across oncology, immunology, inflammation, and metabolic disorders. An initial proof‑of‑concept in Pompe disease (enzyme replacement therapy) supports the ability of AMFA to improve lysosomal targeting; this program is further underpinned by EMA Orphan Drug Designation, strengthening the translational rationale and regulatory pathway for rare indications.
Business Model
- Partnerships and licensing around AMFA‑enabled conjugation and delivery for partner assets;
- Selective internal programs to de‑risk high‑impact indications and create co‑development options.
Intellectual Property
NanoMedSyn’s AMFA chemistry and use are protected by a robust patent estate covering composition, receptor engagement, and therapeutic applications, providing a defensible position across key markets.